Reversed Mutation Rates of KRAS and EGFR Genes in Adenocarcinoma of the Lung in Taiwan and Their Implications.

The article presents a study which discusses the mutation rates of Kirsten ras oncogene homolog gene (KRAS) among patients with nonsmall cell lung cancer (NSCLC). It mentions that the researchers performed mutation analysis of KRAS and correlated its results with clinicopathological features. It affirms that the authors concluded that the KRAS mutation rate is too low in terms of being considered as an important factor in resisting tyrosine kinase inhibitor (TKI).